SPONSOR
RemeGen Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 3, Phase 3
RemeGen Co., Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Myasthenia Gravis, Ocular.
The trial portfolio spans Phase 2, Phase 3, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — RemeGen Co., Ltd.
How many clinical trials has RemeGen Co., Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by RemeGen Co., Ltd., of which 2 are actively recruiting participants. These trials cover conditions including Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Myasthenia Gravis, Ocular. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does RemeGen Co., Ltd. research focus on?
RemeGen Co., Ltd. clinical trials span Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Myasthenia Gravis, Ocular. The research pipeline includes Phase 2, Phase 3, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a RemeGen Co., Ltd. clinical trial?
To participate in a RemeGen Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all RemeGen Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by RemeGen Co., Ltd.
NCT06221748 Phase 2, Phase 3
Recruiting
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Gastric Cancer
NCT07249632 Phase 3
Recruiting
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Myasthenia Gravis, Ocular
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology